TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
1-Year Return
21.62%
This Quarter Return
+16.47%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$1.4B
AUM Growth
+$418M
(+43%)
Cap. Flow
+$310M
Cap. Flow
% of AUM
22.12%
Top 10 Holdings %
Top 10 Hldgs %
35.88%
Holding
163
New
35
Increased
43
Reduced
14
Closed
8
Top Buys
| 1 |
Aurinia Pharmaceuticals
AUPH
|
$32.6M |
| 2 |
BioNTech
BNTX
|
$32.1M |
| 3 |
Relay Therapeutics
RLAY
|
$25.3M |
| 4 |
ITOS
iTeos Therapeutics
ITOS
|
$24.6M |
| 5 |
Immunocore
IMCR
|
$21.8M |
Top Sells
| 1 |
Eli Lilly
LLY
|
$24.4M |
| 2 |
Dynavax Technologies
DVAX
|
$6.68M |
| 3 |
Beam Therapeutics
BEAM
|
$2.45M |
| 4 |
Inhibrx
INBX
|
$2.37M |
| 5 |
CRISPR Therapeutics
CRSP
|
$2.35M |
Sector Composition
| 1 | Healthcare | 95.59% |
| 2 | Technology | 1.47% |
| 3 | Communication Services | 1.22% |
| 4 | Real Estate | 0.34% |
| 5 | Financials | 0.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Exxon Mobil
XOM
$479B
| $821K | 0.06% |
7,004
+5,096
| +267% | +$597K |
|
127
Johnson & Johnson
JNJ
$431B
| $813K | 0.06% |
+5,015
| New | +$813K |
|
128
Verastem
VSTM
$650M
| $807K | 0.06% |
270,000
-271,514
| -50% | -$812K |
|
129
Standard BioTools
LAB
$493M
| $787K | 0.06% |
+407,755
| New | +$787K |
|
130
Pfizer
PFE
$140B
| $745K | 0.05% |
+25,738
| New | +$745K |
|
131
MacroGenics
MGNX
$123M
| $720K | 0.05% |
218,856
| – | – |
|
132
Atara Biotherapeutics
ATRA
$89.9M
| $611K | 0.04% |
75,196
| – | – |
|
133
Puma Biotechnology
PBYI
$257M
| $510K | 0.04% |
200,000
| – | – |
|
|
AFMD
134
DELISTED
Affimed
AFMD
| $498K | 0.04% |
+148,315
| New | +$498K |
|
135
Precigen
PGEN
$1.36B
| $474K | 0.03% |
+500,000
| New | +$474K |
|
|
EGRX
136
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $443K | 0.03% |
118,857
| – | – |
|
137
Invivyd
IVVD
$209M
| $337K | 0.02% |
330,172
+130,172
| +65% | +$133K |
|
138
Amylyx Pharmaceuticals
AMLX
$887M
| $324K | 0.02% |
100,000
| – | – |
|
139
Netflix
NFLX
$534B
| $303K | 0.02% |
427
| – | – |
|
140
American Express
AXP
$230B
| $271K | 0.02% |
1,001
| – | – |
|
141
Athira Pharma
ATHA
$15.3M
| $268K | 0.02% |
600,000
-452,715
| -43% | -$202K |
|
142
GE Aerospace
GE
$299B
| $261K | 0.02% |
1,383
| – | – |
|
143
Allstate
ALL
$54.9B
| $239K | 0.02% |
1,260
| – | – |
|
144
Sherwin-Williams
SHW
$91.2B
| $234K | 0.02% |
+612
| New | +$234K |
|
145
T-Mobile US
TMUS
$284B
| $221K | 0.02% |
+1,071
| New | +$221K |
|
146
United Airlines
UAL
$34.3B
| $221K | 0.02% |
+3,872
| New | +$221K |
|
147
Amazon
AMZN
$2.51T
| $217K | 0.02% |
1,164
| – | – |
|
148
Clorox
CLX
$15.2B
| $201K | 0.01% |
+1,236
| New | +$201K |
|
149
Seres Therapeutics
MCRB
$165M
| $189K | 0.01% |
10,000
-110,356
| -92% | -$2.09M |
|
150
Relmada Therapeutics
RLMD
$45.5M
| $165K | 0.01% |
50,825
-187,049
| -79% | -$606K |
|